 Biologic specimens for intensive immunology and virology studies will be obtained before, during and after exposure to everolimus. Samples will be analyzed at screening, baseline prior to addition of everolimus, and at weeks 8 and 26 while on everolimus, and week 52 6 months post everolimus discontinuation. 